Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm

Detalhes bibliográficos
Autor(a) principal: Rocha, Sónia
Data de Publicação: 2017
Outros Autores: Tejo, Sandra, Ferreira, Eugénia, Trindade, Luís, Rabadão, Eduardo, Marques, Nuno, Saraiva da Cunha, José
Tipo de documento: Artigo
Idioma: eng
por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130
Resumo: Introduction: In Portugal, the prevalence of hepatitis A virus infection has decreased in the past decades, especially in young adults. The aim of this study was to detect the prevalence of antibody to hepatitis A virus in a population observed in our Travel Clinic.Material and Methods: Antibodies against hepatitis A, hepatitis B, hepatitis C and human immunodeficiency virus were tested using standard enzyme immunoassay in patients older than 18. The exclusion criteria were: prior vaccination for hepatitis A virus, previous diagnosis of infection with hepatitis B virus, hepatitis C virus and/or human immunodeficiency virus, foreign travelers and long-term expatriates. We applied an epidemiological survey and data was statistically analyzed with SPSS® 18.0.Results: In the 665 travelers studied, natural immunity to hepatitis A virus was present in 57.6% (n = 383). They were stratified into 8 age groups and for each one hepatitis A immunity was clarified: 5.0% (n = 1) in 18 - 25 years, 32.3% (n = 21) in 26 - 30 years, 40.9% (n = 47) in 31 - 35 years, 45.8% (n = 54) in 36 - 40 years, 68.7% (n = 79) in 41 - 45 years, 70.1% (n = 68) in 46 - 50 years, 80.8% (n = 63) in 51 - 55 years and 87.7% (n = 50) over 56 years old. In those who accepted further screening, positivity for hepatitis B core antibody was found in 0.6% (n = 3) travelers, hepatitis C virus infection in 1.1% (n = 6) and human immunodeficiency virus infection in 0.5% (n = 3) whose previous status was unknown. The most frequent travel destination was sub-Saharan Africa (72.6%; n = 483).Discussion: We found 49.1% (n = 260) travelers under 50 years old susceptible to hepatitis A virus infection and for those between 40 and 50 years, 30.7% (n = 65) still need vaccine protection.Conclusion: Across age groups there is a trend towards lower prevalence of hepatitis A virus antibody, in particular among youngsters, when compared with older Portuguese studies.
id RCAP_3b79eb39db6a3b5946e4607a09cf6722
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/8130
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New ParadigmSeroprevalência do Anticorpo do Vírus na Hepatite A em Viajantes Portugueses: Um Novo ParadigmaHepatitis AHepatitis A AntibodiesHepatitis A VirusHumanPortugalSeroepidemiologic StudiesTravelTravel MedicineViral VaccinesAnticorpos Anti-Hepatite AEstudos SeroepidemiológicosHepatite AMedicina do ViajantePortugalViagemVírus da Hepatite A HumanaIntroduction: In Portugal, the prevalence of hepatitis A virus infection has decreased in the past decades, especially in young adults. The aim of this study was to detect the prevalence of antibody to hepatitis A virus in a population observed in our Travel Clinic.Material and Methods: Antibodies against hepatitis A, hepatitis B, hepatitis C and human immunodeficiency virus were tested using standard enzyme immunoassay in patients older than 18. The exclusion criteria were: prior vaccination for hepatitis A virus, previous diagnosis of infection with hepatitis B virus, hepatitis C virus and/or human immunodeficiency virus, foreign travelers and long-term expatriates. We applied an epidemiological survey and data was statistically analyzed with SPSS® 18.0.Results: In the 665 travelers studied, natural immunity to hepatitis A virus was present in 57.6% (n = 383). They were stratified into 8 age groups and for each one hepatitis A immunity was clarified: 5.0% (n = 1) in 18 - 25 years, 32.3% (n = 21) in 26 - 30 years, 40.9% (n = 47) in 31 - 35 years, 45.8% (n = 54) in 36 - 40 years, 68.7% (n = 79) in 41 - 45 years, 70.1% (n = 68) in 46 - 50 years, 80.8% (n = 63) in 51 - 55 years and 87.7% (n = 50) over 56 years old. In those who accepted further screening, positivity for hepatitis B core antibody was found in 0.6% (n = 3) travelers, hepatitis C virus infection in 1.1% (n = 6) and human immunodeficiency virus infection in 0.5% (n = 3) whose previous status was unknown. The most frequent travel destination was sub-Saharan Africa (72.6%; n = 483).Discussion: We found 49.1% (n = 260) travelers under 50 years old susceptible to hepatitis A virus infection and for those between 40 and 50 years, 30.7% (n = 65) still need vaccine protection.Conclusion: Across age groups there is a trend towards lower prevalence of hepatitis A virus antibody, in particular among youngsters, when compared with older Portuguese studies.Introdução: A prevalência da hepatite A em Portugal tem diminuído nas últimas décadas, sobretudo nos jovens adultos. O objetivo deste estudo foi avaliar a prevalência do anticorpo contra o vírus da hepatite A numa população que recorreu à consulta de Medicina do Viajante.Material e Métodos: Avaliamos a serologia de hepatite A, hepatite B, hepatite C e do vírus da imunodeficiência humana, através de imunoensaio enzimático padrão, de viajantes com idade igual ou superior a 18 anos. Excluímos aqueles previamente vacinados contra o vírus da hepatite A, com diagnóstico prévio de infeção pelos vírus da hepatite B, hepatite C e/ou vírus da imunodeficiência humana, estrangeiros e emigrantes. Aplicamos um inquérito epidemiológico prospetivo e analisamos os dados estatisticamente com o SPSS® versão 18.Resultados: Participaram no estudo 665 viajantes, dos quais 57,6% (n = 383) eram imunes para o vírus da hepatite A. Foram estratificados por oito grupos etários e, para cada um, foi avaliada a presença de imunidade: 5,0% (n = 1) nos 18 - 25 anos, 32,3% (n = 21) nos 26 - 30 anos, 40,9% (n = 47) nos 31 - 35 anos, 45,8% (n = 54) nos 36 - 40 anos, 68,7% (n = 79) nos 41 - 45 anos, 70,1% (n = 68) nos 46 - 50 anos, 80,8% (n = 63) nos 51 - 55 anos e 87,7% (n = 50) com idade igual ou superior a 56 anos. Dos que aceitaram realizar rastreio, detetou-se o anticorpo hepatitis B core em 0,6% (n = 3) viajantes, infeção pelo vírus da hepatite C em 1,1% (n = 6) e pelo vírus da imunodeficiência humana em 0,5% (n = 3), cujos estados serológicos eram desconhecidos. O destino mais frequente foi a África Subsariana (72,6%; n = 483).Discussão: Detetamos 49,1% (n = 260) viajantes suscetíveis a infeção pelo vírus da hepatite A e o grupo dos 40 aos 50 anos de idade, 30,7% (n = 65) ainda necessita de proteção vacinal.Conclusão: A prevalência do anticorpo contra o vírus da hepatite A tem diminuindo na população Portuguesa, aumentando a suscetibilidade a esta infeção nas deslocações a áreas endémicas.Ordem dos Médicos2017-08-31info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfimage/jpegimage/jpegimage/jpegimage/jpegimage/jpegimage/jpegapplication/pdfapplication/vnd.openxmlformats-officedocument.wordprocessingml.documentimage/jpegimage/jpeghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130oai:ojs.www.actamedicaportuguesa.com:article/8130Acta Médica Portuguesa; Vol. 30 No. 7-8 (2017): July-August; 534-540Acta Médica Portuguesa; Vol. 30 N.º 7-8 (2017): Julho-Agosto; 534-5401646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPengporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/5103https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/8692https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/8693https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/8694https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9080https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9081https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9082https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9091https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9261https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9341https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9342Direitos de Autor (c) 2017 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessRocha, SóniaTejo, SandraFerreira, EugéniaTrindade, LuísRabadão, EduardoMarques, NunoSaraiva da Cunha, José2022-12-20T11:05:26Zoai:ojs.www.actamedicaportuguesa.com:article/8130Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:19:33.065603Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm
Seroprevalência do Anticorpo do Vírus na Hepatite A em Viajantes Portugueses: Um Novo Paradigma
title Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm
spellingShingle Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm
Rocha, Sónia
Hepatitis A
Hepatitis A Antibodies
Hepatitis A Virus
Human
Portugal
Seroepidemiologic Studies
Travel
Travel Medicine
Viral Vaccines
Anticorpos Anti-Hepatite A
Estudos Seroepidemiológicos
Hepatite A
Medicina do Viajante
Portugal
Viagem
Vírus da Hepatite A Humana
title_short Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm
title_full Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm
title_fullStr Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm
title_full_unstemmed Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm
title_sort Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm
author Rocha, Sónia
author_facet Rocha, Sónia
Tejo, Sandra
Ferreira, Eugénia
Trindade, Luís
Rabadão, Eduardo
Marques, Nuno
Saraiva da Cunha, José
author_role author
author2 Tejo, Sandra
Ferreira, Eugénia
Trindade, Luís
Rabadão, Eduardo
Marques, Nuno
Saraiva da Cunha, José
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Rocha, Sónia
Tejo, Sandra
Ferreira, Eugénia
Trindade, Luís
Rabadão, Eduardo
Marques, Nuno
Saraiva da Cunha, José
dc.subject.por.fl_str_mv Hepatitis A
Hepatitis A Antibodies
Hepatitis A Virus
Human
Portugal
Seroepidemiologic Studies
Travel
Travel Medicine
Viral Vaccines
Anticorpos Anti-Hepatite A
Estudos Seroepidemiológicos
Hepatite A
Medicina do Viajante
Portugal
Viagem
Vírus da Hepatite A Humana
topic Hepatitis A
Hepatitis A Antibodies
Hepatitis A Virus
Human
Portugal
Seroepidemiologic Studies
Travel
Travel Medicine
Viral Vaccines
Anticorpos Anti-Hepatite A
Estudos Seroepidemiológicos
Hepatite A
Medicina do Viajante
Portugal
Viagem
Vírus da Hepatite A Humana
description Introduction: In Portugal, the prevalence of hepatitis A virus infection has decreased in the past decades, especially in young adults. The aim of this study was to detect the prevalence of antibody to hepatitis A virus in a population observed in our Travel Clinic.Material and Methods: Antibodies against hepatitis A, hepatitis B, hepatitis C and human immunodeficiency virus were tested using standard enzyme immunoassay in patients older than 18. The exclusion criteria were: prior vaccination for hepatitis A virus, previous diagnosis of infection with hepatitis B virus, hepatitis C virus and/or human immunodeficiency virus, foreign travelers and long-term expatriates. We applied an epidemiological survey and data was statistically analyzed with SPSS® 18.0.Results: In the 665 travelers studied, natural immunity to hepatitis A virus was present in 57.6% (n = 383). They were stratified into 8 age groups and for each one hepatitis A immunity was clarified: 5.0% (n = 1) in 18 - 25 years, 32.3% (n = 21) in 26 - 30 years, 40.9% (n = 47) in 31 - 35 years, 45.8% (n = 54) in 36 - 40 years, 68.7% (n = 79) in 41 - 45 years, 70.1% (n = 68) in 46 - 50 years, 80.8% (n = 63) in 51 - 55 years and 87.7% (n = 50) over 56 years old. In those who accepted further screening, positivity for hepatitis B core antibody was found in 0.6% (n = 3) travelers, hepatitis C virus infection in 1.1% (n = 6) and human immunodeficiency virus infection in 0.5% (n = 3) whose previous status was unknown. The most frequent travel destination was sub-Saharan Africa (72.6%; n = 483).Discussion: We found 49.1% (n = 260) travelers under 50 years old susceptible to hepatitis A virus infection and for those between 40 and 50 years, 30.7% (n = 65) still need vaccine protection.Conclusion: Across age groups there is a trend towards lower prevalence of hepatitis A virus antibody, in particular among youngsters, when compared with older Portuguese studies.
publishDate 2017
dc.date.none.fl_str_mv 2017-08-31
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130
oai:ojs.www.actamedicaportuguesa.com:article/8130
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/8130
dc.language.iso.fl_str_mv eng
por
language eng
por
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/5103
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/8692
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/8693
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/8694
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9080
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9081
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9082
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9091
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9261
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9341
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/8130/9342
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2017 Acta Médica Portuguesa
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2017 Acta Médica Portuguesa
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
image/jpeg
image/jpeg
image/jpeg
image/jpeg
image/jpeg
image/jpeg
application/pdf
application/vnd.openxmlformats-officedocument.wordprocessingml.document
image/jpeg
image/jpeg
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 30 No. 7-8 (2017): July-August; 534-540
Acta Médica Portuguesa; Vol. 30 N.º 7-8 (2017): Julho-Agosto; 534-540
1646-0758
0870-399X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130645936472064